Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial
Trial Parameters
Brief Summary
To explore the safety and efficacy of attapulgite in the treatment of obese individuals or overweight/obese individuals with type 2 diabetes.
Eligibility Criteria
Inclusion Criteria: Obese individuals: * Aged 18-60 years, regardless of sex/gender * BMI≥28.0kg/m2 Overweight or obese individuals with type 2 diabetes: * Aged 18-60 years, regardless of sex/gender * BMI≥24.0kg/m2 * HbA1c ≥7.0% and ≤10.0% or the fasting blood glucose ≥7.0 mmol/l and ≤ 13.3 mmol/l at screening * Stable diabetes treatment for at least 6 months or more Exclusion Criteria: * Type 1 diabetes, monogenic diabetes, or diabetes due to pancreatic injury or other secondary diabetes * Severe diabetic complications within three months before the study initiation, including severe hypoglycemia, diabetic ketoacidosis, or infections * Use of weight-affecting products within the past three months or planned use during the study * Weight fluctuation \>5 kg or \>10% within the past three months * Obesity or overweight due to endocrine disorders (such as thyroid dysfunction or Cushing's syndrome) * Uncontrolled hypertension, severe cardiac/hepatic/renal dysfunction * History of gastroint